Posaconazole for the Treatment of Allergic Bronchopulmonary Aspergillosis in Patients with Cystic Fibrosis

Overview

Journal J Antimicrob Chemother

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2019 Feb 27

PMID 30805605

Citations 17

Authors

J Periselneris

L Nwankwo

S Schelenz

A Shah

D Armstrong-James

Affiliations

Soon will be listed here.

Abstract

Objectives: Allergic bronchopulmonary aspergillosis (ABPA) can accelerate lung function decline in patients with cystic fibrosis (CF). Antifungal medication can be used in addition to systemic corticosteroid treatment.

Patients And Methods: We evaluated Aspergillus-specific IgE and the use of therapeutic drug monitoring of triazoles in a retrospective analysis of 32 patients.

Results: There was a significant reduction in Aspergillus IgE with posaconazole but not with other triazoles (P = 0.026). Aspergillus IgE levels were inversely correlated with the therapeutic drug level of posaconazole.

Conclusions: These data suggest that posaconazole is better than comparator azoles at decreasing serological response to Aspergillus and that this response was better with therapeutic levels of posaconazole.

Citing Articles

Revised ISHAM-ABPA working group clinical practice guidelines for diagnosing, classifying and treating allergic bronchopulmonary aspergillosis/mycoses.

Agarwal R, Sehgal I, Muthu V, Denning D, Chakrabarti A, Soundappan K Eur Respir J. 2024; 63(4).

PMID: 38423624 PMC: 10991853. DOI: 10.1183/13993003.00061-2024.

Clinical Manifestations of Human Exposure to Fungi.

Oliveira M, Oliveira D, Lisboa C, Boechat J, Delgado L J Fungi (Basel). 2023; 9(3).

PMID: 36983549 PMC: 10052331. DOI: 10.3390/jof9030381.

Experience of Isavuconazole as a Salvage Therapy in Chronic Pulmonary Fungal Disease.

Nwankwo L, Gilmartin D, Matharu S, Nuh A, Donovan J, Armstrong-James D J Fungi (Basel). 2022; 8(4).

PMID: 35448593 PMC: 9029347. DOI: 10.3390/jof8040362.

Review of current and future therapeutics in ABPA.

Lewington-Gower E, Chan L, Shah A Ther Adv Chronic Dis. 2021; 12:20406223211047003.

PMID: 34729149 PMC: 8543630. DOI: 10.1177/20406223211047003.

It's not all about inhaled treatment: challenges with oral therapy in paediatric respiratory medicine.

Sareen A, Ramphul M, Bhatt J Breathe (Sheff). 2021; 17(1):210005.

PMID: 34295409 PMC: 8291910. DOI: 10.1183/20734735.0005-2021.

References

Walsh T, Raad I, Patterson T, Chandrasekar P, Donowitz G, Graybill R . Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis. 2006; 44(1):2-12. DOI: 10.1086/508774. View

Agarwal R, Dhooria S, Sehgal I, Aggarwal A, Garg M, Saikia B . A randomised trial of voriconazole and prednisolone monotherapy in acute-stage allergic bronchopulmonary aspergillosis complicating asthma. Eur Respir J. 2018; 52(3). DOI: 10.1183/13993003.01159-2018. View

Kraemer R, Delosea N, Ballinari P, Gallati S, Crameri R . Effect of allergic bronchopulmonary aspergillosis on lung function in children with cystic fibrosis. Am J Respir Crit Care Med. 2006; 174(11):1211-20. DOI: 10.1164/rccm.200603-423OC. View

Agarwal R, Dhooria S, Sehgal I, Aggarwal A, Garg M, Saikia B . A Randomized Trial of Itraconazole vs Prednisolone in Acute-Stage Allergic Bronchopulmonary Aspergillosis Complicating Asthma. Chest. 2018; 153(3):656-664. DOI: 10.1016/j.chest.2018.01.005. View

Nelson L, Callerame M, Schwartz R . Aspergillosis and atopy in cystic fibrosis. Am Rev Respir Dis. 1979; 120(4):863-73. DOI: 10.1164/arrd.1979.120.4.863. View

Glackin L, Leen G, Elnazir B, Greally P . Voriconazole in the treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis. Ir Med J. 2009; 102(1):29. View

Stevens D, Moss R, Kurup V, Knutsen A, Greenberger P, Judson M . Allergic bronchopulmonary aspergillosis in cystic fibrosis--state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis. 2003; 37 Suppl 3:S225-64. DOI: 10.1086/376525. View

Burgel P, Paugam A, Hubert D, Martin C . in the cystic fibrosis lung: pros and cons of azole therapy. Infect Drug Resist. 2016; 9:229-238. PMC: 5036609. DOI: 10.2147/IDR.S63621. View

Woolnough K, Richardson M, Newby C, Craner M, Bourne M, Monteiro W . The relationship between biomarkers of fungal allergy and lung damage in asthma. Clin Exp Allergy. 2016; 47(1):48-56. DOI: 10.1111/cea.12848. View

10.

Ricketti A, Greenberger P, Patterson R . Serum IgE as an important aid in management of allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol. 1984; 74(1):68-71. DOI: 10.1016/0091-6749(84)90089-7. View

11.

Baxter C, Denning D, Jones A, Todd A, Moore C, Richardson M . Performance of two Aspergillus IgG EIA assays compared with the precipitin test in chronic and allergic aspergillosis. Clin Microbiol Infect. 2013; 19(4):E197-204. DOI: 10.1111/1469-0691.12133. View

12.

Denning D, Cadranel J, Beigelman-Aubry C, Ader F, Chakrabarti A, Blot S . Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J. 2015; 47(1):45-68. DOI: 10.1183/13993003.00583-2015. View

13.

Chotirmall S, Branagan P, Gunaratnam C, McElvaney N . Aspergillus/allergic bronchopulmonary aspergillosis in an Irish cystic fibrosis population: a diagnostically challenging entity. Respir Care. 2008; 53(8):1035-41. View

14.

Rosenberg M, Patterson R, Roberts M . Immunologic responses to therapy in allergic bronchopulmonary aspergillosis: serum IgE value as an indicator and predictor of disease activity. J Pediatr. 1977; 91(6):914-7. DOI: 10.1016/s0022-3476(77)80889-5. View

15.

Agarwal R, Gupta D, Aggarwal A, Saxena A, Saikia B, Chakrabarti A . Clinical significance of decline in serum IgE levels in allergic bronchopulmonary aspergillosis. Respir Med. 2009; 104(2):204-10. DOI: 10.1016/j.rmed.2009.09.005. View